Stock DNA
Pharmaceuticals: Other
CAD 16 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
2.65
-109.22%
2.96
Revenue and Profits:
Net Sales:
12 Million
(Quarterly Results - Mar 2025)
Net Profit:
0 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
68.87%
0%
68.87%
6 Months
17.24%
0%
17.24%
1 Year
7.59%
0%
7.59%
2 Years
214.81%
0%
214.81%
3 Years
304.76%
0%
304.76%
4 Years
-98.43%
0%
-98.43%
5 Years
-96.83%
0%
-96.83%
IM Cannabis Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
122.91%
EBIT Growth (5y)
-253.92%
EBIT to Interest (avg)
-4.31
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
3.23
Sales to Capital Employed (avg)
2.13
Tax Ratio
14.44%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.64%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.11
EV to EBIT
-2.33
EV to EBITDA
-3.00
EV to Capital Employed
1.03
EV to Sales
0.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-44.04%
ROE (Latest)
-229.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 22 Foreign Institutions (6.99%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
12.50
13.30
-6.02%
Operating Profit (PBDIT) excl Other Income
0.60
0.30
100.00%
Interest
0.00
0.70
-100.00%
Exceptional Items
0.00
0.20
-100.00%
Consolidate Net Profit
0.20
-1.20
116.67%
Operating Profit Margin (Excl OI)
12.60%
-21.50%
3.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -6.02% vs -4.32% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 116.67% vs -9.09% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
54.00
48.80
10.66%
Operating Profit (PBDIT) excl Other Income
-4.80
-9.20
47.83%
Interest
4.50
3.70
21.62%
Exceptional Items
0.20
-0.60
133.33%
Consolidate Net Profit
-11.80
-10.20
-15.69%
Operating Profit Margin (Excl OI)
-129.60%
-249.50%
11.99%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.66% vs -10.13% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -15.69% vs 59.04% in Dec 2023
About IM Cannabis Corp. 
IM Cannabis Corp.
Pharmaceuticals: Other
IM Cannabis Corp., formerly Navasota Resources Inc., is a Canada-based medical cannabis company. The company is focused on offering a full spectrum of government-licensed cannabis products, from generic to good manufacturing practice (GMP) certified and pharmaceutical-grade, for both wholesale and retail clients. The Company operates in the Israeli medical cannabis market by providing intellectual property and services to licensed producers. The Company has three wholly-owned subsidiaries: IMC, incorporated, IMC Portugal and IM Cannabis Canada Inc. The Company also has four partially-owned subsidiaries Adjupharm GmbH, IMC Ventures Ltd., Societe Amig Navasota Mining International S.A.R.L., and Africa Bauxite Corporation.






